Pfizer's 17% Rebound Deemed Unsustainable Due to Valuation Concerns
Pfizer shares have returned 17% since early November yet lack fundamental support for further gains. Valuation analysis and several mitigating factors fail to justify a bullish position on the stock.
1. Pfizer's Unsustainable Rebound
Pfizer shares have posted a 17% total return since early November, outpacing broader market gains. Despite this rally, valuation analysis and various mitigating factors indicate that fundamentals do not support additional upside, leading analysts to recommend against new positions.
Related News
ELF
e.l.f. Beauty Marks 29th Consecutive Sales Growth, Reinvests $58.5M Tariff Refunds
ELF•
NBTX
Nanobiotix Halts Trading to Finalize €75 M Follow-On Offering Pricing
NBTX•
BA
NTSB: Boeing Extended MD-11 Inspection Interval 47% Before Deadly UPS Crash
BA•
STEL
Stellar Bancorp Declares $0.15 Quarterly Dividend Payable June 26
STEL•
META
Meta Lays Off 10% Workforce, Cancels 6,000 Hires as AI Capex Jumps
META•
Sources
SF